Product Name: KinSub2DDLYP
Product Number: PE-01AJV95
Size: 200 µg      Price:99.00
      $US
Peptide Name: KinSub2DDLYP

Product Use: For assaying the phosphotransferase activity of Ephrin type-A receptor 1 protein-tyrosine kinase (EphA1, UniProt ID P21709). The KinSub2DDLYP peptide demonstrated high phosphotransferase activity with EphA1, and exhibited moderate specificity when assayed with over 200 other protein kinases. A listing of other kinases that show appreciable phosphotransferase activity towards this peptide are listed in Table 1.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: KinSub2DDLYP was originally identified using a microarray with peptides that were predicted as optimal substrates for 500 human protein kinases with a proprietary algorithm developed at Kinexus with our academic partners.

Peptide Sequence: GGGEDDLYPYVGGGG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 1411.4 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Peptide Recommended Enzyme: EphA1

Scientific Background: EphA1 is one of several protein kinases that can phosphorylate KinSub2DDLYP. Human EphA1 is a receptor protein-tyrosine kinase of 976 amino acid length, with a predicted molecular mass of 108,067 Da. It is a member of the TK group of protein kinases in the Eph family. This kinase is moderate to highly expressed in most tested human tissues. Orthologues of EphA1 are highly conserved in mammals and birds. EphA1 is activated by binding of ephrin-A1 on a presenting cell, which is likely to induce EphA1 dimerization and autophosphorylation. EphA1 has been implicated in mediating developmental events, particularly in the nervous system (1). EphA1 seems to be a marker of the differentiated normal epidermis, and its downregulation in nonmelanoma skin cancer may contribute to carcinogenesis of these very frequent human tumors. EphA1 represents a new potential prognostic marker and therapeutic target in nonmelanoma skin cancer (2). EphA1 has also been linked with the development of glioblastomas, head and neck cancer and breast carcinomas (pleomorphic lobular).
References

[1] Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol. 2002 Jul;3(7):475-86. PMID: 12094214

[2] Hafner C, Becker B, Landthaler M, Vogt T. Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer. Mod Pathol. 2006 Oct;19(10):1369-77. Epub 2006 Jul 7. PMID: 16862074